Pharma
Commented by Armin Schulz on April 5th, 2023 | 12:25 CEST
BioNTech, BioNxt Solutions, Bayer - The big one is only a matter of time
The biotech and pharmaceutical industry is currently in a constant state of flux, driven by the introduction of new technologies and the fight against global health problems. Producing medicines and therapies to alleviate diseases is of great value to people's health. Against the backdrop of an ageing population in industrialised nations, the sector will continue to be of great importance. A particular focus is on inventing advanced technologies to fight diseases such as cancer, Alzheimer's and Parkinson's. Today we look at three companies in the biotech and pharma sector.
Read
Commented by Juliane Zielonka on March 30th, 2023 | 12:15 CEST
Saturn Oil + Gas, Bayer, Amazon - Big business on a growth path
The oil industry is booming again: since Russia has been severely sanctioned, EU companies are fleeing to their international production sites to operate cost-efficiently. The winner in the energy poker is Saturn Oil & Gas. The Canadian company is now presenting its results for fiscal year 2022. What is clear is how hard the Company has worked on substance to grow steadily. Change is also felt at Bayer in the wake of the CEO change. Research in the field of women's health is discontinued, only one new blockbuster is still in the pipeline, but it is a big one. The fact that the stock market is associated with fear and greed is shown by the jump in AMC's share price. Just one piece of news from Amazon takeover rumors has investors jumping at the chance.
Read
Commented by Nico Popp on March 27th, 2023 | 09:26 CEST
Cost pressure in the healthcare system - how you benefit: Bayer, BioNxt, BioNTech
What do you think of the German healthcare system? While doctors regularly grumble about bureaucracy and patients about long waiting times or other inconsistencies, a new divide is opening up between pharmaceutical companies. Research-based pharmaceutical companies favour long patent protection, while generics manufacturers want more lax rules. We explain the system and highlight opportunities for investors.
Read
Commented by Juliane Zielonka on March 23rd, 2023 | 08:02 CET
BioNxt Solutions, Bayer, BioNTech - These pharma stocks offer growth potential
The risk of cancer is increasing worldwide for people over the age of 50. The reasons for this are lack of sleep and exercise, pre-existing diseases and poor nutrition. It has now also been scientifically proven that permanent stress is a cause of Parkinson's disease. According to the WHO, disabilities and deaths due to Parkinson's are increasing faster worldwide than for any other neurological disease. Pharmaceutical and biotech companies are doing everything they can to improve the quality of life of those affected. The Canadian biotech company BioNxt is working on a comparative study to improve a therapy patch for treating Parkinson's and make accompanying drug products scalable. Bayer subsidiary Bluerock Therapeutics is using data from the Apple Watch to research Parkinson's symptoms. And CEO Uğur Şahin of BioNTech has closed a billion-dollar deal in cancer therapy.
Read
Commented by Fabian Lorenz on March 9th, 2023 | 10:52 CET
BioNTech, Pfizer, Bayer and BioNxt Solutions on the biotech takeover merry-go-round
2023 could become the year of takeovers in the pharmaceutical and biotech sectors. This is what the experts at PwC expect. Thus, at the JP Morgan industry conference in San Francisco, not only were takeover candidates discussed but billion-dollar transactions were reported. One reason is the Inflation Reduction Act in the USA. This allows negotiations on drug prices. To prevent sales declines, Big Pharma must invest in new top sellers. And it is already doing so. The latest takeover rumor comes from BioNTech partner Pfizer. At BioNTech, the negative news currently outweighs the positive. Whether Bayer will take action with the boss or be taken over itself is not yet entirely clear. But there are also opportunities for investors in the smallcap sector. Take BioNxt Solutions, for example - the Canadian company with its operational focus in Germany recently secured new patents, and the share price has jumped.
Read
Commented by Fabian Lorenz on March 8th, 2023 | 16:22 CET
Nel share slumps, a 60% chance with Bayer, Almonty Industries and BASF
The Nel share was one of the big daily losers yesterday. As a result, the upward trend has finally been broken, and analysts' opinions differ widely. Berenberg sees the BASF share as a hold after the publication of the quarterly figures. The price target is EUR 55. The figures are in line with expectations. However, the end of share buybacks and concerns about future competitiveness weigh on the stock. By contrast, analysts see up to 60% upside potential for Bayer. Almonty Industries is benefiting from the boom in electromobility and also defense spending. As the leading tungsten producer outside China, analysts suspect it could soon come to a bidding war.
Read
Commented by André Will-Laudien on October 12th, 2022 | 11:31 CEST
Biotech in the scope: BioNTech, XPhyto Therapeutics, MorphoSys, Valneva - The cards are reshuffled!
Cancer remains one of the greatest afflictions of our time, along with cardiovascular disease. Despite the tremendous progress already made in the fight against cancer, there remains an unmet medical need for many types of cancer. Cancer was responsible for nearly 10 million deaths worldwide in 2020. Other diseases, such as Alzheimer's and Parkinson's, also continue to be the focus of research. How is the biotech industry faring after the pandemic and during the stock market storm?
Read
Commented by Juliane Zielonka on September 30th, 2022 | 10:59 CEST
Biogen, XPhyto, BioNTech: Alzheimer's disease, depression, cancer - Pharma for life
About 350 million people worldwide are affected by depression, a disorder of the brain. Each person also has a 16 to 20% chance of becoming depressed. Reason enough for the Canadian Company XPhyto Therapeutics to research a drug that is not addictive and can defeat the mental health-related medical condition. This week, Biogen, among others, achieved a breakthrough with an active substance against Alzheimer's disease. And if you follow the Bundesliga closely, you may be aware of the cases of testicular cancer among the players. Now BioNTech senses a new opportunity...
Read
Commented by Carsten Mainitz on August 31st, 2022 | 13:35 CEST
BYD, Kleos Space, Bayer - Great opportunities in laggards
Although stock markets continue to correct, driven by geopolitical uncertainties and interest rate fears, some sectors have defied the generally adverse market conditions in recent weeks. For example, renewable energy stocks such as Plug Power more than doubled on the back of Joe Biden's climate change package. However, most companies from other sectors remain at discounted levels despite excellent prospects, which should offer investors good long-term entry opportunities.
Read
Commented by Juliane Zielonka on August 18th, 2022 | 13:50 CEST
Apple, Tocvan Ventures, Valneva - More returns through innovation or risk hedging?
Innovations are hailed as market drivers. The more innovative a company is, the more likely it is to stay ahead of the competition. But this requires loyal customers who also support these innovations. And Apple has just such a customer base, setting a good example that loyalty must be rewarded for innovation. In contrast, pharmaceutical company Valneva has the challenge of exposure to different development cycles in the healthcare market. If only because of the duration of clinical studies, which rightly have to go well before a new product comes onto the market. This time, nature lovers could benefit. Those who find all this too volatile and unpredictable should once again turn to commodities as a hedge. With Tocvan Ventures, a candidate is in the running that looks very closely at optimizing the costs of its operations - to the benefit of investors.
Read